FDCP
GILD icon

Foster Dykema Cabot & Partners’s Gilead Sciences GILD Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.93K Hold
39
– – ﹤0.01% 280
2026
Q1 		$5.43K Hold
39
– – ﹤0.01% 274
2025
Q4 		$4.79K Sell
39
-476
-92% -$57.8K ﹤0.01% 286
2025
Q3 		$57.2K Buy
+515
New +$58.5K ﹤0.01% 199
2024
Q3 		– Sell
-200
Closed -$13.7K – 520
2024
Q2 		$13.7K Buy
+200
New +$13.3K ﹤0.01% 250

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Foster Dykema Cabot & Partners's GILD Position: Q2 2026 in Review

Foster Dykema Cabot & Partners held its Gilead Sciences (GILD) position steady in Q2 2026 at 39 shares worth $4.93K. The position accounts for ﹤0.01% of the portfolio, ranked #280.

Foster Dykema Cabot & Partners first reported a position in GILD in Q2 2024 and has held it in 5 quarters since. The position peaked at $57.2K in Q3 2025. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Foster Dykema Cabot & Partners held 39 shares of Gilead Sciences worth $4.93K as of Q2 2026.
  • Foster Dykema Cabot & Partners left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up ﹤0.01% of Foster Dykema Cabot & Partners's portfolio in Q2 2026, its #280 holding.
  • Foster Dykema Cabot & Partners first reported a position in Gilead Sciences in Q2 2024 and has held it in 5 quarters since.
  • Foster Dykema Cabot & Partners's Gilead Sciences position peaked at $57.2K in Q3 2025.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Foster Dykema Cabot & Partners's 13F filing for Q2 2026, filed 11 Aug 2026.